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MicroRNAs (miRs) have emerged recently as important regulators of gene expression
in the cell. Frequently dysregulated in cancer, miRs have shed new light on molecular
mechanisms of oncogenesis, and have generated substantial interest as biomarkers, and
novel therapeutic agents and targets. Recently, a number of studies have examined miR
biology in Ewing sarcoma. Findings indicate that alterations in miR expression in Ewing
Sarcoma are widespread, involve both EWS/Ets oncogenic fusion-dependent and indepen-
dent mechanisms, and contribute to malignant phenotypes. miRs with prognostic potential
have been identified, and several preclinical studies suggest that miR manipulation could
be therapeutically useful in this aggressive disease. These and future studies of miR biol-
ogy stand to expand our understanding of Ewing sarcoma pathogenesis, and may identify
new biomarkers and treatment options.
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INTRODUCTION
MicroRNAs (miRs) represent a recently discovered novel class
of cellular bioactive molecules with important functions in the
regulation of gene expression in normal physiology and disease
(Ghildiyal and Zamore, 2009). MiRs are short (20–30 nt) single-
stranded RNA molecules that bind to protein-coding messenger
RNA (mRNA) molecules, predominantly in the 3′ untranslated
region (UTR) (Ghildiyal and Zamore, 2009). This binding results
in decreased synthesis of the coded protein, by a number of
mechanisms including increased mRNA degradation and inhi-
bition of translation (Ghildiyal and Zamore, 2009). The binding is
sequence-specific, but involves a limited (∼6–8) nt match (Bartel,
2009). Thus, individual miRs have many possible mRNA targets,
while, as a group, miRs contribute to the control of expression of
much of the genome.
MicroRNAs are derived from hairpin-shaped, double-stranded
precursors (pre-miRs) by the action of a protein complex con-
taining the Dicer gene product (Davis and Hata, 2009; Kim et al.,
2009; Winter et al., 2009). Most of these precursors are in turn
derived from longer primary transcripts (pri-miRs) by the action
of the microprocessor complex containing the proteins Drosha
and DGCR8 (Davis and Hata, 2009; Kim et al., 2009; Winter et al.,
2009). Although some miRs are embedded in protein-coding genes
and co-regulated with the parent mRNA, approximately one-half
are derived from independent, non-protein-coding transcripts
under control of RNA Polymerase II-driven promoters (Davis and
Hata, 2009; Kim et al., 2009; Winter et al., 2009). The expression
of such miRs is subject to the same mechanisms of promoter reg-
ulation as protein-coding genes, including the action of specific
transcription factors. Relatively little is currently known about the
precise mechanisms controlling miR expression under conditions
of normal homeostasis and in disease.
In cancer, miRs function as context-dependent tumor sup-
pressors or oncogenes, capable, through their molecular func-
tion as regulators of gene expression, of modifying all aspects
of tumorigenesis, including tumor cell proliferation/apoptosis,
invasion/metastasis, stem-like properties, and angiogenesis
(Sotiropoulou et al., 2009; Visone and Croce, 2009). Importantly,
miRs represent promising new therapeutic agents or/and targets,
a concept borne out in preclinical studies (Weidhaas et al., 2007;
Trang et al., 2008; Wang and Wu, 2009; Kasinski and Slack, 2011;
Nana-Sinkam and Croce, 2011). Such studies have shown that
administration of chemical mimics of tumor suppressive miR, or
chemical antagonists of pro-tumorigenic miRs, can have potent
effects on tumor growth or/and dissemination in disease ani-
mal models. Examples of successful preclinical therapeutic trials
in pediatric cancers include miR-380-5p replacement in neurob-
lastoma (Swarbrick et al., 2010), and miR replacement/anti-miR
combination therapy, involving miR-100 and miR-371 clusters,
in hepatoblastoma (Cairo et al., 2010). Thus, miR manipulation
in vivo can affect disease phenotypes. Some miR-based therapies
have already moved ahead to clinical trials, including blockade of
miR-122 for chronic viral hepatitis (Cho, 2010; Wahid et al., 2010).
Recently, a number of studies have examined the biology of
miRs in Ewing Sarcoma. The purpose of this minireview is to sum-
marize the findings of these studies, and discuss insights that they
have provided into disease pathogenesis, and potential options for
improved disease subclassification and therapy.
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MicroRNAs IN EWS/Fli1-DRIVEN ONCOGENESIS
The pathogenesis of the vast majority of Ewing Sarcomas is dri-
ven by EWS/Ets fusion oncoproteins, which arise from recurrent
chromosomal translocations and are necessary for tumorigenesis
(Janknecht, 2005; Jedlicka, 2010; Toomey et al., 2010). EWS/Ets
fusions, with EWS/Fli1 being the most common, consist of the
amino terminus of the EWS gene and the carboxy terminus,
including the DNA-binding domain, of an Ets transcription fac-
tor gene. Transcriptional activity, including both activation and
repression, is central to EWS/Ets oncogenic action (Toomey et al.,
2010; Sankar et al., 2012). Additionally, EWS/Ets downstream
genes include other transcriptional regulators (Toomey et al.,
2010). Furthermore, the EWS protein may play a role in miR pro-
cessing (Gregory et al., 2004; Sohn et al., 2012). Since transcription
and processing represent important mechanisms of control of miR
levels in the cell (Davis and Hata, 2009; Kim et al., 2009; Winter
et al., 2009), it was reasonable to postulate that EWS/Ets fusions
affect the expression of miRs in Ewing Sarcoma, and that con-
sequent alterations in miR levels contribute to the execution of
the EWS/Ets-driven oncogenic program. Identification and char-
acterization of EWS/Ets-regulated miRs was undertaken by several
groups.
Ban et al. (2011) used transient siRNA-mediated knock-down
to deplete EWS/Fli1 in five different Ewing Sarcoma cell lines.
They then compared miR levels between control and EWS/Fli1-
depleted cells, and between five Ewing Sarcoma patient tumors
and mesenchymal stem cells (MSCs, the presumed cells of Ewing
Sarcoma origin) from six different individuals, using a multi-
plexed RT-qPCR platform. This approach identified 15 upregu-
lated and 14 downregulated miRs across all comparison groups.
MiR-145 was the miR most consistently changed, namely reduced
upon EWS/Fli1 depletion, and underexpressed in Ewing Sarcoma
relative to MSCs. In support of a tumor suppressive role, the
authors showed that miR-145 replacement results in inhibition of
anchorage-independent growth of Ewing Sarcoma cells. Further,
they showed direct repression of EWS/Fli1 by miR-145, suggest-
ing the existence of a miR-mediated positive feedback loop for
augmenting EWS/Fli1 protein levels in the cell. A similar feedback
loop has been identified by Riggi et al. (2010), as discussed in more
detail below. A subsequent study has shown that miR-708, another
EWS/Fli1-downregulated miR identified in the studies of Ban et
al., modulates chemotherapy responsiveness in Ewing Sarcoma
(Robin et al., 2012).
McKinsey et al. (2011) took the approach of stably knock-
ing down EWS/Fli1 in Ewing Sarcoma A673 cells, using lentivi-
rally delivered shRNAs, and probing for changes in miR lev-
els using a miR microarray platform. This approach identified
29 upregulated, and 31 downregulated miRs upon EWS/Fli1
depletion. Focusing on a group of miRs upregulated following
EWS/Fli1 knock-down (miRs 22, 100, 125b, 221/222, 27a, and
29a), they showed that levels of these miRs vary specifically with
EWS/Fli1 manipulation, including EWS/Fli1 depletion with dif-
ferent shRNAs and ectopic EWS/Fli1 expression in a heterologous
fusion-negative cell line, and that these miRs are underexpressed in
Ewing Sarcoma cell lines relative to MSCs. With respect to func-
tion, the authors demonstrated that forced expression of these
miRs results in inhibition of growth in A673 cells, and that a sub-
set of the miRs targets components of IGF signaling. These studies
suggest that repression of select miRs promotes EWS/Fli1-driven
oncogenesis by augmenting IGF pathway activity.
Franzetti et al. (2012) also profiled miRs in A673 cells following
EWS/Fli1 depletion, but used an inducible shRNA approach and
Illumina BeadChip technology as the profiling platform. These
authors identified 34 upregulated, and 36 downregulated miRs
upon EWS/Fli1 depletion. Focusing on miRs targeting CD99,
they showed that miR-30a-5p, a miR downregulated by EWS/Fli1,
contributes to the control of CD99 expression by EWS/Fli1.
The authors further showed that overexpression of miR-30a-5p
inhibits proliferation of and invasion by Ewing Sarcoma cells.
A number of studies have provided evidence in support of a
MSC origin for Ewing Sarcoma (Castillero-Trejo et al., 2005; Riggi
et al., 2005; Tirode et al., 2007). Thus, an alternative approach to
identifying pathogenic miRs, including those driven by EWS/Fli1,
in Ewing Sarcoma is comparison of miR expression profiles
between Ewing Sarcoma and MSCs. Such an approach was taken by
De Vito et al. (2011a). They identified 11 enriched and 24 depleted
miRs in two Ewing Sarcoma cell lines (A673 and TC252) relative to
MSCs. Among depleted miRs were multiple members of the let-7
family, previously shown to be tumor suppressive in other can-
cers. The authors showed that EWS/Fli1 directly represses let-7a
expression, and that forced replacement of let-7a inhibits Ewing
Sarcoma tumor xenograft growth, in part through regulation of
HMGA2 levels.
Table 1 summarizes Ewing Sarcoma-associated miR alterations,
as identified by the above studies. Several observations can be
made. First, while some miRs (shown in bold) were identified in
multiple studies, many miR changes were specific to a given study.
Particularly striking are the differences between the EWS/Fli1-
dependent expression profiles of Ban et al. (2011) versus those of
McKinsey et al. (2011) and Franzetti et al. (2012) Several possible
explanations exist. First, the use of transient EWS/Fli1 depletion
by Ban et al. in contrast to the stable depletion used in the other
two studies, may have enriched for miRs more immediately down-
stream of the fusion oncoprotein. Alternatively, the simultaneous
comparison across multiple cell lines and tumors, as applied by
Ban et al. may have imposed a very stringent filter that elimi-
nated the detection of some miR alterations. Lastly, some of the
differences may be accounted for by different controls and miR
profiling platforms. Differences in profiling platforms may also be
responsible for some of the differences between the miR alterations
identified by McKinsey et al. and Franzetti et al. since both studies
used the same cell line (A673), and same general approach (stable
EWS/Fli1 knock-down). However, different controls, shRNAs, and
culture conditions, as well as the precise depth of EWS/Fli1 knock-
down, represent additional variables. Given the differences among
studies using a similar experimental approach (EWS/Fli1 deple-
tion), it is equally striking how similar the profiles are between the
more divergent approaches taken by McKinsey et al. (depletion of
EWS/Fli1) and De Vito et al. (2011a) (profiling of Ewing Sar-
coma cell lines versus MSCs). The profile similarities between
these studies suggest that, as observed with gene expression pro-
files (Tirode et al., 2007), depletion of EWS/Fli1 can give rise to a
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Table 1 | Alterations in miR expression as a function of EWS/Fli1
or/and presumed cell of origin in Ewing sarcoma.
Ban et al.
(2011)
McKinsey
et al. (2011)
Franzetti
et al. (2012)
De Vito et al.
(2011a)
miRs up
in EwS
500 17/20a/
106a/93
34c 19a/19b
126* 484 573 17/20a/106a/
106b/93
93* 92a/92b/25 150 103/107
505 15b 486 15b
128 103/107 363 18a
126 324-5p 556
9 423-3p 9*
101 320 632
425* let-7d 675
592 106b* 520a*
340* 130b 106a
505* 760 302b*
652 378 9
150 532-3p 346
20a* 665 1229
886-5p 504
574-5p 663
940 1270
296-3p 204
186 490
181d 20b
622
105
miRs
down in
EwS
145 146a/146b-
5p
452 let-7 Family
424 21 145 199a-
5p/199a-3p
21 22 144 27a/27b
214* 100/99a/99b 143 24
214 125b 205 193a
28-5p 221/222 509 886-3p
424* 584 190 145
27a* 199a-
5p/199a-3p
223 23a/23b
22* 29a 31 22
409-3p 27a/27b 767-3p 143
21* 193b 30a-3p 100
125b 549 511 221/222
708 95 365 31
135b 127-3p 517c 125b
941 224 21
203 450
574-3p 574
186* 668
493 222
922 34a
30a 199b
(Continued)
Ban et al.
(2011)
McKinsey
et al. (2011)
Franzetti
et al. (2012)
De Vito et al.
(2011a)
603 542-3p
137
30a-5p
146a
328
Data from expression profiling studies using EWS/Fli1 depletion (McKinsey et al.,
2011; Franzetti et al., 2012), Ewing Sarcoma versus mesenchymal stem cell com-
parison (De Vito et al., 2011a), or both (Ban et al., 2011). MiRs with shared seed
sequence are grouped. MiRs in bold were detected as differentially expressed in
at least two of the studies. MiRs in italics were shown to affect cancer pheno-
type(s) in Ewing Sarcoma. “*” Denotes the generally less abundantly expressed
miR strand. See text and references for further details.
miR profile resembling MSCs. This would appear to provide fur-
ther evidence that MSCs, or closely related cells, may be the cells of
Ewing Sarcoma origin. Other noteworthy trends discernible from
a cross-study comparison of miR alterations include the fairly
consistent upregulation of members of the paralogous 17∼ 92a,
106b∼ 25, and 106a∼ 363 “oncomiR” clusters, and downregu-
lation of miR-145. The biological consequences of most of the
EWS/Fli1-related miR alterations identified in the above profiling
studies await characterization.
MicroRNA ALTERATIONS IN TUMOR CELL SUBPOPULATIONS
Tumors are inherently heterogeneous, and contain subpopulations
of cells with unequal potential for tumor-initiation and mainte-
nance. So-called cancer stem cells (CSCs) have been proposed
to drive the initiation and maintenance or tumors, but defining
their identity and impact remains a challenge for cancer biol-
ogists (Magee et al., 2012). Recently, a number of studies have
explored the CSC concept in Ewing Sarcoma. Evidence has been
presented in favor (Suva et al., 2009), and against (Jiang et al.,
2010), CD133 expression as an important marker of Ewing Sar-
coma cells with CSC-like properties, while another study identified
ALDH expression as an alternative CSC marker (Awad et al., 2010).
Expression of CD57 may be another phenotypic marker of Ewing
Sarcoma cells with CSC-like properties (Wahl et al., 2010). MiRs
have been widely implicated in the biology of normal stem cells
and CSCs. To date, the role of miR biology as a function of CSC-
like status in Ewing Sarcoma has been investigated in the CD133
model. One study, examining Ewing Sarcoma initiation in pedi-
atric MSCs, identified miR-145 as an EWS/Fli1-repressed miR, and
miR-145 repression, in turn, as a means to augment expression of
EWS/Fli1 itself, as well as expression of the stemness-associated
transcription factor Sox2 (Riggi et al., 2010). In subsequent work
(De Vito et al., 2011b), the same group examined global miR
expression differences between CD133+ and CD133− cell popula-
tions. Specifically, they compared the miR profiles of CD133+ and
CD133− subpopulations from two Ewing Sarcoma tumors, pedi-
atric MSCs stably expressing retrovirally introduced EWS/Fli1, and
one Ewing Sarcoma cell line (STA-ET-8.2). The authors found
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more depleted than enriched miRs in CD133+ subpopulations,
some of which were shared between Ewing Sarcoma tumors and
EWS/Fli1-expressing MSCs, and identified downregulation of the
miR processing factor TARBP2 as a mechanism for miR depletion
in CD133+ cells. They further showed that TARBP2 depletion in
Ewing Sarcoma cell lines results in downregulation of a group of
miRs depleted in CD133+ cells and enhanced tumor xenograft
growth, while augmentation of TARBP2 activity, via treatment
with the fluoroquinolone-class antibiotic enoxacin, results in
upregulation of these miRs and impaired tumor xenograft growth.
Lastly, systemic administration of miR-143 or miR-145, two of the
miRs downregulated in CD133+ cells, resulted in inhibition of
tumor growth. Together, these findings support a role for miRs
in the enhanced tumorigenicity of CD133+ Ewing Sarcoma cell
subpopulations.
MicroRNA EXPRESSION AND DISEASE PROGNOSIS
Nakatani et al. (2012) examined the potential role of miRs as pre-
dictive biomarkers in Ewing Sarcoma. In this investigation, global
miR microarray profiling was performed on 34 primary Ewing
Sarcoma tumors, comparing the expression profiles of patients
with early relapse (median time from diagnosis 14 months, range
2–29 months) to those without clinical relapse (median follow-up
139 months, range 26–217 months). This analysis identified five
miRs (34a, 23a, 92a, 490-3p, and 130b) that were significantly
associated with both event-free and overall survival. In further
analyses, low levels of miR-34a emerged as a particularly robust
predictor of early relapse. In functional studies, the authors showed
that miR-34a inhibits anchorage-independent growth of Ewing
Sarcoma cell lines, and sensitizes to vincristine and doxorubicin.
Consistent with the established role of p53 as a regulator of miR-
34a expression, miR-34a levels were found to be low in Ewing
Sarcoma cell lines with p53 inactivating mutations. Moreover, one
tumor with low miR-34a levels was found to have a p53 mutation.
This study examined p53 status in only a small number of tumors
(six total). A question of interest for future studies is the extent
of overlap between inactivation of the p53 pathway and miR-34a
downregulation in Ewing Sarcoma tumors. On the one hand, miR-
34a may emerge as a very useful surrogate marker of p53 pathway
status, potentially independent of mechanism of p53 inactivation.
Alternatively, miR-34a may identify a new subgroup of patients
with poor prognosis.
MECHANISMS RESPONSIBLE FOR ALTERED MicroRNA
EXPRESSION IN EWING SARCOMA
What are the mechanisms responsible for the wide-ranging alter-
ations in miR expression in Ewing Sarcoma? MiR biogenesis in
the cell is regulated at multiple levels, including precursor (pri-
miR) transcription (or transcription of the parent gene for miRs
derived from protein-coding mRNAs), pri-miR to pre-miR pro-
cessing, nuclear-cytoplasmic transport, pre-miR to (mature) miR
processing, and stability/turnover. Thus far, in Ewing Sarcoma,
evidence has been presented for regulation of precursor transcrip-
tion and pre-miR to miR processing. With respect to transcrip-
tional control, McKinsey et al. (2011) showed that a group of
EWS/Fli1-repressed miRs also demonstrate downregulation of the
precursor (pri-miR) transcript, consistent with a transcriptional
regulatory mechanism. Further, three other studies of EWS/Fli1-
repressed miRs [miRs 30a (Franzetti et al., 2012) and 145 (Riggi
et al., 2010), and let-7a (De Vito et al., 2011a)] showed EWS/Fli1-
dependent downregulation of the activity of the putative miR
promoters in reporter assays. Most of the studies also exam-
ined binding of endogenous EWS/Fli1 to the presumed relevant
miR upstream regulatory regions, using chromatin immunopre-
cipitation (ChIP). Interestingly, two studies found enrichment of
EWS/Fli1 (De Vito et al., 2011a; McKinsey et al., 2011) at such
regions, while two others did not (Ban et al., 2011; Franzetti
et al., 2012). The tentative conclusion from these studies is that
both direct and indirect mechanisms appear to contribute to
transcriptional miR repression by EWS/Fli1, with detailed mech-
anisms awaiting further elucidation. Indirect mechanisms could
involve the action of EWS/Fli1-induced repressors, like Nkx2.2
(Owen et al., 2008), NR0B1 (Kinsey et al., 2006), and EZH2
(Richter et al., 2009). Alternatively, EWS/Fli1 could repress miR
transcriptional activators. Thus far, studies of transcriptional miR
regulation in Ewing Sarcoma have only addressed downregulated
miRs. Potential mechanisms of transcriptional activation of miR
expression by EWS/Fli1 remain to be examined.
Studies have also provided evidence for alterations in miR
processing in Ewing Sarcoma. De Vito et al. (2011a) identified
upregulation of Lin-28B and hnRNPA1, both inhibitors of let-7
maturation. As discussed above, in a subsequent study, the same
group also showed impaired miR maturation due to diminished
levels of TARBP2 in the CD133+ subpopulation of Ewing Sar-
coma cells (De Vito et al., 2011b). The mechanisms of Lin-28B
and hnRNPA1 upregulation, as well as CD133+ subpopulation-
specific TARBP2 downregulation, remain to be determined. An
intriguing, and currently largely unexplored, possibility is a role
for the unrearranged copy of EWS or/and the EWS component of
EWS/Ets fusions, in miR processing in Ewing Sarcoma. EWS has
been identified in the (pri to pre) miR processing complex (Gre-
gory et al., 2004), and a recent study suggests that it can promote
the processing of some miR(s) (Sohn et al., 2012). Roles in the pro-
motion of miR processing have also recently been demonstrated
for the other two members of the TET (TLS/EWS/TAF15) fam-
ily, FUS/TLS (Morlando et al., 2012), and TAF15 (Ballarino et al.,
2012). Whether EWS has a more general role in miR processing,
whether potential haploinsufficiency for this function affects miR
biogenesis in Ewing Sarcoma, and whether EWS/Ets fusions inter-
fere with this function, through EWS/Ets-EWS protein-protein
interactions (Embree et al., 2009) or through gain-of-function
miR processing activity of EWS/Ets, remain to be determined.
Lastly, Dicer, a key effector of miR maturation in the cell, is an
EWS/Fli1-upregulated gene (Kinsey et al., 2006). The functional
consequences of this to miR regulation and disease phenotype in
Ewing Sarcoma are currently unknown, but changes in Dicer lev-
els can profoundly influence cancer phenotypes (Lambertz et al.,
2010; Nittner et al., 2012). The above mechanisms are summarized
in Figure 1.
CONCLUSION AND PERSPECTIVES
What have we learned from miR studies in Ewing Sarcoma thus
far? We have gained new insight into disease biology, and identified
new candidate biomarkers and therapeutic targets. MiRs represent
Frontiers in Oncology | Pediatric Oncology March 2013 | Volume 3 | Article 65 | 4
Dylla et al. MicroRNAs in Ewing sarcoma
FIGURE 1 | Known and hypothetical mechanisms of altered microRNA
(miR) expression in Ewing sarcoma. Basic pathway for biogenesis of
majority of miRs is shown, including those derived from non-coding RNA
precursor transcripts (pri-miR) and protein-coding mRNAs. EWS/Fli1
represses some miRs at the transcriptional level, through direct and indirect
mechanisms, and likely also transcriptionally activates other miRs. EWS is a
component of the Drosha/DGCR8 miR processing complex, and the copy
number of the wild-type intact form is reduced in Ewing sarcomas with
EWS-containing fusions. EWS/Fli1 can also interact with EWS. The
consequences of this to miR biogenesis are currently unknown. Dicer is
upregulated by EWS/Fli1; the consequences of this in Ewing Sarcoma are
unknown, but Dicer levels impact oncogenesis in other cancers. TARBP2
downregulation in CD133+ Ewing Sarcoma cells results in diminished
expression of a number of miRs. (Pol: RNA Polymerase.) See text and
references for more detail.
a novel and unique mechanism of regulation of gene expression,
which can affect protein levels without dramatic changes in mRNA
levels. Thus, understanding of miR-mediated pathways can reveal
new oncogenic mechanisms not easily accessible to other method-
ologies like RNA-based gene expression profiling. To this end, miR
studies thus far have revealed a new mechanism for augmenting
EWS/Fli1 protein levels (Riggi et al., 2010; Ban et al., 2011), new
mechanisms of induction of known upregulated genes (CD99)
and pathways (IGF) in Ewing Sarcoma (McKinsey et al., 2011;
Franzetti et al., 2012), and new players in the EWS/Fli1-driven
oncogenic program (HMGA2 and Sox2) (Riggi et al., 2010; De
Vito et al., 2011a). Of clinical relevance, the work of Nakatani
et al. has identified a potential miR-based biomarker of aggres-
sive disease (miR-34) (Nakatani et al., 2012), which could have
real clinical utility given the relative ease of assaying miR levels in
tumor specimens (Hui et al., 2009). Preclinical animal studies have
also suggested potential candidate strategies for miR-based thera-
peutics, including replacement of miR-145 (Riggi et al., 2010; De
Vito et al., 2011b), miR-143 (De Vito et al., 2011b) and let-7a (De
Vito et al., 2011a), and augmentation of TARBP2 activity (De Vito
et al., 2011b). Many interesting unanswered questions remain. A
great deal remains to be learned about the mechanisms responsible
for altered miR expression in Ewing Sarcoma. Similarly, the biol-
ogy of individual miRs with altered expression patterns remains
largely uncharacterized. Particularly intriguing is the role of miRs
like miR-21 and miRs-221/222, identified as upregulated and pro-
oncogenic in most malignancies (Sotiropoulou et al., 2009; Visone
and Croce, 2009), but observed to be downregulated in most pro-
filing analyses of Ewing Sarcoma (see Table 1). Further, to date,
studies of miR biology in Ewing Sarcoma have been carried out in
the context of the common EWS/Fli1 fusion. It will be of interest to
determine how miR expression and function differ in the context
of the other, less common, EWS/Ets fusions, as well as the more
divergent non-EWS/Ets fusions discovered recently (Sankar and
Lessnick, 2011). Will miR-based therapies make it to the clinic?
As with all new concepts and methodologies, only time and more
rigorous science will tell.
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